Chimeric antigen receptor T cells targeting CD79b show efficacy in lymphoma with or without co-targeting CD19

PURPOSE: T cells engineered to express a chimeric antigen receptor (CAR) against CD19 have recently been FDA-approved for the treatment of relapsed or refractory large B cell lymphoma. Despite the success and curative potential of CD19 CAR T cells, several reports describing disease relapse due to a...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Ormhøj, Maria, Scarfò, Irene, Cabral, Maria L., Bailey, Stefanie R., Lorrey, Selena J., Bouffard, Amanda A., Castano, Ana P., Larson, Rebecca C., Riley, Lauren S., Schmidts, Andrea, Choi, Bryan D., Andersen, Rikke S., Cédile, Oriane, Nyvold, Charlotte G., Christensen, Jacob H., Gjerstorff, Morten F., Ditzel, Henrik J., Weinstock, David M., Barington, Torben, Frigault, Matthew J., Maus, Marcela V.
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6891163/
https://ncbi.nlm.nih.gov/pubmed/31439577
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-1337
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados